Editas Stock: Analysts’ Recommendations

Kenneth Smith - Author

Nov. 16 2018, Updated 11:01 a.m. ET

Analysts’ recommendations

In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.

Article continues below advertisement

Peers’ ratings

In comparison, analysts have given Bluebird Bio (BLUE), Regenxbio (RGNX), and Spark Therapeutics (ONCE) a mean rating of 1.95, 2.33, and 2.17, respectively, and target prices of $199.12, $89.08, and $63.24, respectively.

Price performance

Editas Medicine stock rose from $31.40 on April 30 to $41.01 on June 20. Since then, the stock has been trending lower.

Amid the broader market turmoil in October, Editas Medicine stock saw selling pressure and fell to $24.39 on October 24. After an initial price increase in November, the company’s shares have been falling in the last few trading sessions. Currently, the shares are trading at $27 levels in November.

Editas Medicine’s enterprise value is $1.07 billion, while its enterprise value-to-revenues ratio is 36.30. The company’s price-to-sales ratio is 43.33, while the price-to-book ratio is 5.51.

Editas Medicine’s current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 13.10. In comparison, CRISPR Therapeutics (CRSP), Regenxbio (RGNX), and Spark Therapeutics’ (ONCE) current ratios are 15.40, 20.20, and 10.70, respectively.


Latest Spark Therapeutics Inc News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.